(R) -6-(2-fluorophenyl) -N-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl) -5,6-dihydrobenzo[h]quinazolin-2-amine CAS 1234356-69-4

Pwodwi Deskripsyon:

Non pwodwi:

(R) -6-(2-fluorophenyl) -N-(3-(2-((2-methoxyethyl)amino) ethyl) -5,6-dihydrobenzo[h]quinazolin-2-amine CAS NON: 1234356-69-4

 

Sinonim:

Derazantinib;

Derazantinib (ARQ-087);

ARQ-087; ARQ087;

 

Chimik & Pwopriyete fizik:

Aparans: Solid oswa poud

Assay: ≥98.0%

Dansite: 1.218±0.06 g / cm3 (Predicted)

Bouyi pwen: 615.1±65.0 ° C (predi)

PKa: 9.04±0.19 (predi)

Flash Point: 325.8±34.3° C

Presyon Vapor: 0.0±1.8 mmHg nan 25 ° C

Endeks refraksyon: 1.632

 

Derazantinib (ARQ-087) se yon atp konpetitif kinaz inibitor; ekspozisyon aktivite ki pisan kont FGFR1-3 chondrocytes ak IC50s nan 4.5, 1.8, ak 4.5 nM, respektivman. ARQ-087, ke yo rele tou Derazantinib, se yon rcepteurs kwasans oral (FGFR) inibitor ak pwopriyete antitomor. FGFR jwe yon wol nan regleman an nan konpotman kle selile ki gen ladan pwopagasyon, diferansyasyon selile ak sou sa. Se dysregulation FGFR konsidere kom yon chofe nan kanse miltip. ARQ 087 mare FGFR ak efektivman inibit aktivasyon an nan FGFR konsa ka siprime tumorigenesis ak kwasans imobilye.

 

Si ou enterese nan pwodwi nou yo oswa ou gen nenpot kesyon, tanpri santi yo lib yo kontakte nou!

 

Pwodwi anba patant yo ofri pou R & D rezon selman. Sepandan, denye responsablite a bay manti selman ak achte a.

Baj popilè: (r) -6-(2-fluorophenyl) -n-(3-(2-((2-methoxyethyl)amino)ethyl)fleksib)l) -5,6-dihydrobenzo[h]quinazolin-2-amine cas 1234356-69-4, manifaktire, founise, faktori, achte, nan machandiz

• On: R428 (BGB324) CAS 1037624-75-1
• Pwochen: AZD-7594 CAS 1196509-60-0